Inhibrx Biosciences (INBX) Operating Margin: 2023-2025
Historic Operating Margin for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to 1,062.94%.
- Inhibrx Biosciences' Operating Margin was N/A to 1,062.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 1,728.54%, marking a year-over-year change of. This contributed to the annual value of -165,724.00% for FY2024, which is 15354506.00% down from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Operating Margin is 1,062.94%, which was up 21.90% from 871.98% recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Operating Margin ranged from a high of 3,001.27% in Q2 2024 and a low of -257,447.06% during Q2 2023.
- Moreover, its 3-year median value for Operating Margin was 871.98% (2025), whereas its average is -38,205.41%.
- Examining YoY changes over the last 5 years, Inhibrx Biosciences' Operating Margin showed a top increase of 26,044,833bps in 2024 and a maximum decrease of 4,452,476bps in 2024.
- Over the past 3 years, Inhibrx Biosciences' Operating Margin (Quarterly) stood at -5,403.24% in 2023, then tumbled by 4,452,476bps to -49,928.00% in 2024, then slumped by 212,928bps to 1,062.94% in 2025.
- Its last three reported values are 1,062.94% in Q3 2025, 871.98% for Q2 2025, and 1,595.43% during Q1 2025.